How to Sequence Therapies in Waldenström Macroglobulinemia
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Link
https://link.springer.com/content/pdf/10.1007/s11864-021-00890-9.pdf
Reference94 articles.
1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.
2. Cao X, Medeiros LJ, Xia Y, Wang X, Thomas SK, Loghavi S, et al. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma. 2016;57(5):1104–13.
3. Castillo JJ, Itchaki G, Gustine JN, Meid K, Flynn CA, Demos MG, et al. A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenstrom macroglobulinemia. Leuk Lymphoma. 2020;61(6):1388–94.
4. Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, et al. Progression risk stratification of asymptomatic Waldenstrom macroglobulinemia. J Clin Oncol. 2019;37(16):1403–11.
5. •• Treon SP, et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med. 2012;367(9):826–33 This was the seminal manuscript in which the discovery of the MYD88 L265P mutation was first described.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Waldenstrom Macroglobulinemia;Comprehensive Hematology and Stem Cell Research;2024
2. Role of CXCL12/CXCR4 Axis in the Pathogenesis of Hematological Malignancies;Reference Module in Biomedical Sciences;2024
3. Transformed Waldenström Macroglobulinemia Responsive to Tafasitamab Plus Lenalidomide: A Case Report;Cureus;2022-12-11
4. Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy;Pharmaceutics;2022-07-25
5. The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements;Clinical and Experimental Medicine;2022-03-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3